Latest period
$4.05B
YoY change
+0.1%
5Y CAGR
+11.8%
Peak year (2025)
$4.18B
Latest annual
$4.18B
Total Liabilities history chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Latest: $4.18B
Total Liabilities growth chart for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
Latest: +0.1%
Total Liabilities history table for Alnylam Pharmaceuticals (ALNY) from 2002 to 2025
| 2025 | $4.18B | +0.1% | +$4.26M | ||
| 2024 | $4.17B | +3.0% | +$122.37M | ||
| 2023 | $4.05B | +9.3% | +$345.94M | ||
| 2022 | $3.70B | +21.3% | +$649.48M | ||
| 2021 | $3.06B | +27.8% | +$664.29M | ||
| 2020 | $2.39B | +150.0% | +$1.43B | ||
| 2019 | $956.44M | +250.6% | +$683.61M | ||
| 2018 | $272.84M | +19.5% | +$44.54M | ||
| 2017 | $228.30M | -33.4% | −$114.29M | ||
| 2016 | $342.59M | +181.3% | +$220.79M | ||
| 2015 | $121.80M | -15.0% | −$21.53M | ||
| 2014 | $143.33M | -4.6% | −$6.86M | ||
| 2013 | $150.18M | -2.1% | −$3.28M | ||
| 2012 | $153.47M | -6.4% | −$10.45M | ||
| 2011 | $163.92M | -30.3% | −$71.11M | ||
| 2010 | $235.03M | -22.5% | −$68.39M | ||
| 2009 | $303.42M | -13.9% | −$49.13M | ||
| 2008 | $352.55M | +19.7% | +$57.93M | ||
| 2007 | $294.62M | +658.7% | +$255.79M | ||
| 2006 | $38.83M | +6.2% | +$2.26M | ||
| 2005 | $36.57M | +83.2% | +$16.60M | ||
| 2004 | $19.96M | -67.7% | −$41.92M | ||
| 2003 | $61.89M | +198.2% | +$41.13M | ||
| 2002 | $20.76M | — | — |
- 2025$4.18B+0.1%
- 2024$4.17B+3.0%
- 2023$4.05B+9.3%
- 2022$3.70B+21.3%
- 2021$3.06B+27.8%
- 2020$2.39B+150.0%
- 2019$956.44M+250.6%
- 2018$272.84M+19.5%
- 2017$228.30M-33.4%
- 2016$342.59M+181.3%
- 2015$121.80M-15.0%
- 2014$143.33M-4.6%
- 2013$150.18M-2.1%
- 2012$153.47M-6.4%
- 2011$163.92M-30.3%
- 2010$235.03M-22.5%
- 2009$303.42M-13.9%
- 2008$352.55M+19.7%
- 2007$294.62M+658.7%
- 2006$38.83M+6.2%
- 2005$36.57M+83.2%
- 2004$19.96M-67.7%
- 2003$61.89M+198.2%
- 2002$20.76M—
Total Liabilities values are taken from Alnylam Pharmaceuticals's reported balance sheets (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About Total Liabilities at Alnylam Pharmaceuticals (ALNY)
According to Alnylam Pharmaceuticals's latest reported financial statements, the company's latest reported total liabilities is $4.05B. Total liabilities sum everything the company owes at the end of each reporting period — accounts payable, accrued expenses, debt, lease obligations, and other claims — as filed on the balance sheet. Compare with total assets and total equity for solvency context.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual total liabilities for Alnylam Pharmaceuticals (ALNY) came in at $4.18B – edged up 0.1% year-over-year.
Over 2020–2025 (5 years), Alnylam Pharmaceuticals total liabilities expanded at a +11.8% compound annual rate, with mixed annual results across the window.
The highest annual total liabilities of $4.18B was reported in 2025. The lowest in the available history was $19.96M in 2004.
Alnylam Pharmaceuticals Total Liabilities by Year
Alnylam Pharmaceuticals Total Liabilities 2025: $4.18B
In 2025, Alnylam Pharmaceuticals reported total liabilities of $4.18B, edged up 0.1% from 2024. This figure represents the highest annual value in the available history.
Alnylam Pharmaceuticals Total Liabilities 2024: $4.17B
Alnylam Pharmaceuticals total liabilities in 2024 was $4.17B, edged up 3.0% from 2023.
Alnylam Pharmaceuticals Total Liabilities 2023: $4.05B
2023's total liabilities for Alnylam Pharmaceuticals came in at $4.05B, grew 9.3% from 2022.
Alnylam Pharmaceuticals Total Liabilities 2022: $3.70B
Alnylam Pharmaceuticals posted total liabilities of $3.70B in 2022, grew 21.3% from 2021.
Alnylam Pharmaceuticals Total Liabilities 2021: $3.06B
Alnylam Pharmaceuticals total liabilities in 2021 was $3.06B.
See more financial history for Alnylam Pharmaceuticals (ALNY).
Sector peers by Total Liabilities
Healthcare peers of Alnylam Pharmaceuticals (ALNY), ranked by their latest total liabilities
| $207.88B | |
| $137.19B | |
| $117.67B | |
| $85.94B | |
| $84.20B | |
| $81.93B | |
| $65.36B | |
| $54.86B |
- $207.88B
- $137.19B
- $117.67B
- $85.94B
- $84.20B
- $81.93B
- $65.36B
- $54.86B
Frequently asked questions
Alnylam Pharmaceuticals (ALNY) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation